Pharmacological treatment options for cryopyrin-associated periodic syndromes

References

• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–3732.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550.
   PubMed Web of Science ®Google Scholar
• Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–265.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol. 2012;28:137–161.
   PubMed Web of Science ®Google Scholar
• Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015;74(11):2043–2049.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56(4):1273–1285.
   PubMed Web of Science ®Google Scholar
• Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011;70(3):495–499.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340–3348.
   PubMed Web of Science ®Google Scholar
• Feldmann J, Prieur A-M, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198–203.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–305.
   PubMed Web of Science ®Google Scholar
• Touitou I. The registry of Hereditary auto-inflammatory Disorders Mutations – infevers. 2017 [cited 2017 Mar 12]. Available from: http://fmf.igh.cnrs.fr/ISSAID/infevers/
   Google Scholar
• Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011;63(11):3625–3632.
   PubMed Web of Science ®Google Scholar
• Saito M, Nishikomori R, Kambe N, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood. 2008;111(4):2132–2141.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Gonzalez-Roca E, Souto A, et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2015;74(3):603–610.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Aksentijevich I, Wood GM, et al. Brief report: cryopyrin-associated periodic syndrome caused by a myeloid-restricted somatic NLRP3 mutation. Arthritis Rheum. 2015;67(9):2482–2486.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2017;76:942–947.
   PubMed Web of Science ®Google Scholar
• Rosengren S, Mueller JL, Anderson JP, et al. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J Allergy Clin Immunol. 2007;119(4):991–996.
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–325.
   PubMed Web of Science ®Google Scholar
• Janssen R, Verhard E, Lankester A, et al. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2004;50(10):3329–3333.
   PubMed Web of Science ®Google Scholar
• Haverkamp MH, Van de Vosse E, Goldbach-Mansky R, et al. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). Clin Exp Immunol. 2014;177(3):720–731.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007;56(9):3138–3148.
   PubMed Web of Science ®Google Scholar
• Tassi S, Carta S, Delfino L, et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci U S A. 2010;107(21):9789–9794.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206(5):1029–1036.
   PubMed Web of Science ®Google Scholar
• Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678–685.
   PubMed Web of Science ®Google Scholar
• Neven B, Prieur A-M, Quartier Dit Maire P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol. 2008;4(9):481–489.
   PubMedGoogle Scholar
• Houx L, Hachulla E, Kone-Paut I, et al. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study. Arthritis Rheum. 2015;67(11):3027–3036.
   Web of Science ®Google Scholar
• Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001;108(4):615–620.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364(9447):1779–1785.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004;50(2):607–612.
   PubMed Web of Science ®Google Scholar
• Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 2002;46(9):2445–2452.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–2371.
   PubMed Web of Science ®Google Scholar
• Hill SC, Namde M, Dwyer A, et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol. 2007;37(2):145–152.
   PubMed Web of Science ®Google Scholar
• Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol. 2001;19(1):103–106.
   PubMed Web of Science ®Google Scholar
• Dollfus H, Häfner R, Hofmann HM, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol. 2000;118(10):1386–1392.
   PubMedGoogle Scholar
• Hoffman HM, Wolfe F, Belomestnov P, et al. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin. 2008;24(9):2531–2543.
   PubMed Web of Science ®Google Scholar
• Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010;157(2):310–315.e1.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202.
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636–1644.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine resistant familial Mediterranean fever – A randomized, double blind, placebo-controlled trial. Arthritis Rheumatol. 2016;69(4):854–862.
   Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13(3):R91.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Tremoulet AH, Jain S, Kim S, et al. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016;48:70–75.
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Moltó A, Ea H-K, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80(2):178–182.
   PubMed Web of Science ®Google Scholar
• Van Asseldonk EJ, Van Poppel PCM, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol. 2015;160(2):155–162.
   PubMed Web of Science ®Google Scholar
• Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905–1915.
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517–1526.
   PubMed Web of Science ®Google Scholar
• Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115(3):288–292.
   PubMed Web of Science ®Google Scholar
• Lazaros G, Imazio M, Brucato A, et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J Cardiovasc Med (Hagerstown). 2016;17(4):256–262.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Hajj-Ali R, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66(9):2570–2579.
   PubMed Web of Science ®Google Scholar
• Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67(7):943–950.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 2014;41(8):1703–1711.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Inflammation in chronic kidney disease and cardiovascular disease – the role of genetics and interleukin-1 receptor antagonist (IL-1ra). 2017 [cited 2017 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT00897715
   Google Scholar
• Krause, K, Tsianakas, A, Wagner, N, et al. Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2016;139(4):1311–1320.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–1286.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. A 3-arm proof of concept study of AIN457, ACZ885 or corticosteroids in patients with polymyalgia rheumatica. 2015 [cited 2017 Mar 24.]. Available from: https://clinicaltrials.gov/ct2/show/NCT01364389
   Google Scholar
• Hensen J, Howard CP, Walter V, et al. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;39(6):524–531.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597–605.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, et al. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;31:15–27.
   PubMed Web of Science ®Google Scholar
• Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142(12):1591–1597.
   PubMedGoogle Scholar
• Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis. 2013;5(6):315–329.
   PubMedGoogle Scholar
• Cantarini L, Lucherini OM, Frediani B, et al. Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol. 2011;24(4):827–836.
   PubMed Web of Science ®Google Scholar
• Snegireva LS, Kostik MM, Caroli F, et al. Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications. Rheumatology (Oxford). 2013;52(9):1731–1732.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–592.
   PubMed Web of Science ®Google Scholar
• Bachove I, Chang C. Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes. Open Access Rheumatol. 2014;6:15–25.
   PubMedGoogle Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003;348(25):2583–2584.
   PubMed Web of Science ®Google Scholar
• FDA. Kineret. Product information. [cited 2017 Mar 14]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf
   Google Scholar
• EMA. Kineret. Product information. [cited 2017 Mar 15]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000363/human_med_000874.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011;63(3):840–849.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64.
   PubMed Web of Science ®Google Scholar
• Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258–267.
   PubMed Web of Science ®Google Scholar
• Yang B-B, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85–94.
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64(7):2375–2386.
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford). 2008;47(3):309–310.
   PubMed Web of Science ®Google Scholar
• Fox E, Jayaprakash N, Pham T-H, et al. The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol. 2010;223(1–2):138–140.
   PubMed Web of Science ®Google Scholar
• Miyamae T, Inaba Y, Nishimura G, et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr Rheumatol Online J. 2010;8:9.
   PubMed Web of Science ®Google Scholar
• Kullenberg T, Löfqvist M, Leinonen M, et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499–1506.
   PubMed Web of Science ®Google Scholar
• LaRock CN, Todd J, LaRock DL, et al. IL-1beta is an innate immune sensor of microbial proteolysis. Sci Immunol. 2016 Aug;1(2). pii: eaah3539. doi: 10.1126/sciimmunol.aah3539.
   PubMedGoogle Scholar
• Buescher ES, Malinowska I. Soluble receptors and cytokine antagonists in human milk. Pediatr Res. 1996;40(6):839–844.
   PubMed Web of Science ®Google Scholar
• Chang Z, Spong CY, Jesus AA, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014;66(11):3227–3232.
   PubMed Web of Science ®Google Scholar
• Youngstein T, Hoffmann P, Lane T, et al. International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors. Pediatr Rheumatol. 2015;13(Suppl 1):O67.
   Google Scholar
• FDA. Rilonacept. Product information. 2012 [cited 2017 Mar 14]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf
   Google Scholar
• EMA. Rilonacept. Product information. 2012 [cited 2017 Mar 14]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001047/human_med_000653.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res. 2010;3:1–8.
   PubMedGoogle Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9(1):47–52.
   PubMed Web of Science ®Google Scholar
• Hoffman HM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther. 2009;9(4):519–531.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443–2452.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34(10):2091–2103.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Setting the cytokine trap for autoimmunity. Nat Med. 2003;9(1):20–22.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432–2442.
   PubMed Web of Science ®Google Scholar
• FDA. Canakinumab product information. 2016 [cited 2017 Mar 14]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2016/125319s084lbl.pdf
   Google Scholar
• EMA. Canakinumab. Product information. 2017 [cited 2017 Mar 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf
   Google Scholar
• Rondeau J-M, Ramage P, Zurini M, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151–1160.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–18.
   PubMedGoogle Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–2425.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Ramos E, Blank N, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13(1):R34.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095–2102.
   PubMed Web of Science ®Google Scholar
• Alten R, Gram H, Joosten LA, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hofer F, Endres T, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016;55(4):689–696.
   PubMed Web of Science ®Google Scholar
• Sibley CH, Chioato A, Felix S, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis. 2015;74(9):1714–1719.
   PubMed Web of Science ®Google Scholar
• Russo RA, Melo-Gomes S, Lachmann HJ, et al. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford). 2014;53(4):665–670.
   PubMed Web of Science ®Google Scholar
• Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15(1):R33.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hawkins PN, Van der Poll T, et al. Safety and efficacy of canakinumab in patients with CAPS: interim results from the beta-confident registry [abstract]. Arthritis Rheumatol. 2015;67(suppl 10):2015.
   Google Scholar
• Handok.co.kr. New bio drug, HL2351. 2015 [cited 2017 Mar 22]. Available from: https://www.handok.co.kr/english/media/news_view.asp?seq=764
   Google Scholar
• clinicaltrials.gov. HL2351 CAPS phase II study. 2016 [cited 2017 Mar 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02853084
   Google Scholar
• Walker UA, Hoffman HM, Williams R, et al. Brief report: severe inflammation following vaccination against streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol. 2016;68(2):516–520.
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Hoffman HM, Van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology. 2017. in press.
   Google Scholar
• Brydges SD, Broderick L, McGeough MD, et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest. 2013;123(11):4695–4705.
   PubMed Web of Science ®Google Scholar
• McKie EA, Reid JL, Mistry PC, et al. A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One. 2016;11(3):e0150018.
   PubMed Web of Science ®Google Scholar
• Masters SL, Simon A, Aksentijevich I, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621–668.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–2748.
   PubMed Web of Science ®Google Scholar
• Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem. 2010;285(27):20607–20614.
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol. 2013;425(1):94–111.
   PubMed Web of Science ®Google Scholar
• Issafras H, Corbin JA, Goldfine ID, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014;348(1):202–215.
   PubMed Web of Science ®Google Scholar
• Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs. 2011;3(1):49–60.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Seyahi E, Fresko I, et al. One year in review 2016: Behçet’s syndrome. Clin Exp Rheumatol. 2016;34(6 Suppl 102):10–22.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–241.
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35(8):1654–1662.
   PubMed Web of Science ®Google Scholar
• Goh AX, Bertin-Maghit S, Ping Yeo S, et al. A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy. MAbs. 2014;6(3):765–773.
   PubMed Web of Science ®Google Scholar
• De Almeida L, Khare S, Misharin AV, et al. The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease. Immunity. 2015;43(2):264–276.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AAB, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255.
   PubMed Web of Science ®Google Scholar
• Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005;175(4):2630–2634.
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516.
   PubMed Web of Science ®Google Scholar